These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 4975184)
1. Chemotherapy in the management of bladder tumours. Gibson GR Aust N Z J Surg; 1969 Feb; 38(3):281-3. PubMed ID: 4975184 [No Abstract] [Full Text] [Related]
2. [The harmfulness of intravesical instillations of thiotepa in cases of vesico-renal reflux]. Rampal M; Alimi JC; Pons G; Fiquet JM J Urol Nephrol (Paris); 1978 Mar; 84(3):271-4. PubMed ID: 417193 [No Abstract] [Full Text] [Related]
3. Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma. Burnand KG; Boyd PJ; Mayo ME; Shuttleworth KE; Lloyd-Davies RW Br J Urol; 1976 Feb; 48(1):55-9. PubMed ID: 817761 [TBL] [Abstract][Full Text] [Related]
6. Intravesical thiotepa in the treatment of transitional cell bladder carcinoma. Mitchell RJ Br J Urol; 1971 Apr; 43(2):185-8. PubMed ID: 4996214 [No Abstract] [Full Text] [Related]
7. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy. Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547 [TBL] [Abstract][Full Text] [Related]
8. [Comparative study of 3 series of patients treated respectively with thiotepa, adriamycin and cisplatin]. Nogueira March JL; Ojea A; Jamardo D; Figueiredo L Actas Urol Esp; 1984; 8(4):325-8. PubMed ID: 6435407 [No Abstract] [Full Text] [Related]
10. Thiotepa effects on urinary cytology in the interpretation of transitional cell cancer. Droller MJ; Erozan YS J Urol; 1985 Oct; 134(4):671-4. PubMed ID: 3928906 [TBL] [Abstract][Full Text] [Related]
11. [New experience with cytostatics, especially their intra-arterial use in bladder tumors]. Reuter JH Z Urol Nephrol; 1966 Feb; 59(2):125-8. PubMed ID: 4964957 [No Abstract] [Full Text] [Related]
12. The management of superficial bladder cancer. Soloway MS Cancer; 1980 Apr; 45(7 Suppl):1856-65. PubMed ID: 6768441 [No Abstract] [Full Text] [Related]
13. The FISH test for the diagnosis, surveillance, and prognosis of transitional cell carcinoma of the bladder. Haddad FS J Med Liban; 2008; 56(4):230-2. PubMed ID: 19115598 [TBL] [Abstract][Full Text] [Related]
14. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Huncharek M; McGarry R; Kupelnick B Anticancer Res; 2001; 21(1B):765-9. PubMed ID: 11299841 [TBL] [Abstract][Full Text] [Related]
16. Pancytopenia and generalized sepsis following treatment of cancer of the bladder with instillations of triethylene thiophosphoramide. Bruce D; Edgcomb JH J Urol; 1967 Mar; 97(3):482-5. PubMed ID: 4960046 [No Abstract] [Full Text] [Related]
17. Intravesical and systemic chemotherapy in the management of superficial bladder cancer. Soloway MS Urol Clin North Am; 1984 Nov; 11(4):623-35. PubMed ID: 6438857 [TBL] [Abstract][Full Text] [Related]
18. Acute nonlymphocytic leukemia after thiotepa instillation into the bladder: report of 2 cases and review of the literature. Silberberg JM; Zarrabi MH J Urol; 1987 Aug; 138(2):402-3. PubMed ID: 3110436 [TBL] [Abstract][Full Text] [Related]
19. Systemic chemotherapy for urothelial transitional cell carcinoma: an overview of toxicity. Moulder SL; Roth BJ Semin Urol Oncol; 2001 Aug; 19(3):194-201. PubMed ID: 11561987 [TBL] [Abstract][Full Text] [Related]
20. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. David KA; Milowsky MI; Ritchey J; Carroll PR; Nanus DM J Urol; 2007 Aug; 178(2):451-4. PubMed ID: 17561135 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]